Antivirals are an important measure to prevent severe disease in vulnerable people with COVID-19.  But there have been concerns antivirals could lead to rebound infections — the resurgence of viral load following the completion of the medication. So what do the latest studies say? Also, we speak to an expert informing the parliamentary inquiry into long COVID about how to best care for patients.  Guest: Professor Tania Sorrell University of Sydney References:  SARS-CoV-2 rebound with and without antivirals Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study Submission—Inquiry into long COVID and repeated COVID infections